Jazz Pharmaceuticals Plc (JAZZ)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Jazz Pharmaceuticals Plc (JAZZ)
Go deeper and ask any question about JAZZ
Company Performance
Current Price
as of Sep 13, 2024$108.79
P/E Ratio
19.43
Market Cap
$6.72B
Description
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Metrics
Overview
- HQDublin, DU
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerJAZZ
- Price$108.79+2.20%
Trading Information
- Market Cap$6.72B
- Float96.51%
- Average Daily Volume (1m)770,465
- Average Daily Volume (3m)702,836
- EPS$6.28
Company
- Revenue$3.91B
- Rev Growth (1yr)6.95%
- Net Income$168.57M
- Gross Margin74.10%
- EBITDA Margin35.40%
- EBITDA$362.48M
- EV$11.24B
- EV/Revenue2.88
- P/E19.43
- P/S1.94
Documents
SEC Filings
Factset Street Account
Earnings Calls
Wikipedia